ARTICLE | Clinical News
Probuphine buprenorphine regulatory update
September 28, 2015 7:00 AM UTC
Braeburn resubmitted an NDA to FDA for Probuphine buprenorphine for maintenance treatment of opioid addiction. The company said it expects a 6-month review for the application. Probuphine is a subcutaneous rod implant for continuous 6-month delivery of buprenorphine using Titan’s ProNeura technology. ...